DISRUPTIVE GPCR LEAD DISCOVERY PLATFORM DELIVERING NEW AND SAFER THERAPEUTICS

Project description

Intelligent discovery platform for better drug development

New drug development and clinical trials takes about 15 years and costs on average EUR 2.3 billion with a success rate of around 12 %. EU funding has enabled InterAx Biotech to develop a systems biology and artificial intelligence-based platform for drug candidate selection with built-in in vivo predictability to dramatically reduce animal testing (60-80 %) and increase probability of success in clinical trials. Their custom-designed services focus on G-protein coupled receptors, which are targets of 40 % of existing drugs. Pharmaceutical and biotech companies can outsource critical stages in drug discovery at reduced expenses and shorter time to market (10 years) – a win-win for the companies as well as the consumers.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › computer and information sciences › artificial intelligence
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• social sciences › economics and business › business and management › business models

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

INTERAX BIOTECH AG

Net EU contribution

€ 1 745 217,25

Address

Park Innovaare
5234 Villingen
Switzerland

Region

Schweiz/Suisse/Svizzera › Nordwestschweiz › Aargau

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 747 950,25